Translational research:CARTiEr study

Elucidation of the kinetics and mechanism of action of EPHB4-CAR-T cells in the human body:Phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors with expression of EPHB4 receptor - Elucidation of the kinetics and mechanism of action of EPHB4-CAR-T cells in the human body:Phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors with expression of EPHB4 receptor

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030240137

Enrollment

Registered

2024-06-03

Start date

2024-06-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ewing's sarcoma or solid tumors diagnosed as advanced relapsed with no standard treatment or refract

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients enrolled in CARTiEr study 2.Written consent has been obtained from the patient for this ancillary study.

Exclusion criteria

Exclusion criteria: 1.Written consent has not been obtained from the patient for this ancillary study. 2.Patients who are regarded as inappropriate for enrollment by investigators.

Design outcomes

Primary

Measure	Time frame
Incidence of Secondary Cancer Incidence of delayed toxicity	—

Secondary

Measure	Time frame
Overall survival:OS CAR gene copy number CAR-positive cells number in peripheral blood Phenotypic Analysis TCR Repatoir Analysis Plasma protein measurement scRNA sequencing analysis Immunostaining of tumor specimens CAR gene expression analysis and immunostaining of secondary cancer specimens Functional analysis of CAR-T cells	—

Contacts

Public ContactToshihiro Suzuki

National Cancer Center Hospital

cartier_core@east.ncc.go.jp+81-4-7133-1111

Outcome results